Date of Award
M.S. in Pharmaceutical Science
Pharmaceutics and Drug Delivery
Michael A. Repka
Cyclosporine (CSA) is a highly potent immunosuppressant drug and has been used to treat rheumatoid arthritis, psoriasis, organ rejection post-transplant, and chronic dry eye disease. The objective of this investigation was to increase the CSA residence time on the ocular surface using solid lipid nanoparticles (SLNs) and its in-situ gel formulation (CSA-SLN-IG), for treatment of dry eye disease. CSA loaded SLNs (CSA-SLN) were prepared with the homogenization method, using Precirol ® ATO 5 as a solid lipid and Tween® 80 and Poloxamer 188 as surfactants. Prepared SLNs were optimized based on particle size, zeta potential (ZP), PDI, assay and stability. CSA-SLN in-situ gels (CSA-SLN-IG) were developed using gellan gum as the gelling agent and rheological properties were evaluated. DSC analysis shothat there was no interaction between lipid and drug. Optimized CSA-SLN shothe particle size, PDI, ZP and assay to be121.20± 5.20 nm, 0.4 ±0.04, -24 ± 1, 95 ± 0.5% respectively. CSA-SLN was stable at refrigerated and room temperature conditions over one month and no significant changes were observed before and after autoclaving up to one month. CSA-SLN-IG prepared with 0.3% gellan gum shoimmediate gel formation with a gel residence time of more than 24 hours, the viscosity of 27.90± 2.80 cP and an assay of 85 ± 0.5%.Therefore, CSA-SLN and CSA-SLN-IG could be considered as an alternative approach for dry eye disease.
Senapati, Samir Shyambabu, "In-Situ Gel of Cyclosporine A – Loaded Solid Lipid Nanoparticles for Topical Occular Delivery for Dry Eye Disease" (2019). Electronic Theses and Dissertations. 1688.